ArticleNanomaterials (Basel, Switzerland)2025
Advancing Skin Rejuvenation Through Ultrasound-Enhanced Non-Invasive Delivery of Hyaluronic Acid Nanoparticles.
Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
High-molecular-weight hyaluronic acid (HMw-HA) is widely used for skin rejuvenation and anti-aging. However, its rapid degradation and <24 h cutaneous residence limit its therapeutic potential. Cross-linked HA fillers were developed to improve longevity, but their high viscosity and invasive administration may reduce biocompatibility and patient comfort. To overcome these challenges, we developed a biocompatible nanocarrier based on quaternized starch (Q-starch) that encapsulates linear HMw-HA into nanoparticles (NPs) of ~100 nm with a ζ-potential of ~-35 mV. These NPs retained spherical morphology over seven days without aggregation. The resulting HMw-HA-NPs significantly improved HA stability and extended its skin residence time compared to commercially available HA, while preserving its biological function to stimulate collagen production in murine models. To enable non-invasive delivery, we applied low-frequency ultrasound (LFUS), which transiently enhanced skin permeability, facilitated deeper NPs penetration, and further elevated collagen at day 14. Altogether, this strategy offers a promising needle-free alternative to traditional HA treatments by improving stability, skin penetration, and therapeutic efficacy. The combination of HMw-HA-NPs with LFUS addresses key limitations of current dermo-esthetic therapies and supports the development of patient-friendly skin rejuvenation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.